All patients
Age < 65y (younger) Age > 65y ECOG 0 ECOG 1 Gender, female Gender, male metastasis (liver ) previous nephrectomy (no) previous nephrectomy (yes) Risk favorable (IMDC) Risk favorable (MSKCC) Risk intermediate (IMDC) Risk intermediate (MSKCC) Risk poor (IMDC) Risk poor (MSKCC) smoker (current or former) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
mRCC - L1 - PDL1 positive, anti-PD-(L)1 vs. sunitinib, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results JAVELIN Renal 101( PDL1>1%), 2019 0.69 [0.58; 0.83]
0.69 [0.58 ; 0.83 ] JAVELIN Renal 101( PDL1>1%), 2019 1 0% 560 NA not evaluable PFS (extension)detailed results JAVELIN Renal 101( PDL1>1%), 2019 0.62 [0.49; 0.78]
0.62 [0.49 ; 0.78 ] JAVELIN Renal 101( PDL1>1%), 2019 1 0% 560 NA not evaluable progression or deaths (PFS)detailed results IMmotion-150 (At - PDL1>1%), 2018 1.03 [0.63; 1.68]
IMmotion-150 (AtB - PDL1>1%), 2018 0.64 [0.38; 1.08]
JAVELIN Renal 101( PDL1>1%), 2019 0.61 [0.47; 0.79]
0.71 [0.52 ; 0.97 ] IMmotion-150 (At - PDL1>1%), 2018, IMmotion-150 (AtB - PDL1>1%), 2018, JAVELIN Renal 101( PDL1>1%), 2019 3 43% 784 moderate not evaluable objective responses (ORR)detailed results IMmotion-150 (At - PDL1>1%), 2018 1.06 [0.46; 2.42]
IMmotion-150 (AtB - PDL1>1%), 2018 2.34 [1.05; 5.20]
JAVELIN Renal 101( PDL1>1%), 2019 3.39 [2.38; 4.82]
2.19 [1.11 ; 4.33 ] IMmotion-150 (At - PDL1>1%), 2018, IMmotion-150 (AtB - PDL1>1%), 2018, JAVELIN Renal 101( PDL1>1%), 2019 3 70% 784 moderate not evaluable 0.2 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-06 16:06 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 152
- treatments: 367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,1561,854,374,953,672,1080,1560,1073,862,1562,1565,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,1563